We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for trastuzumab emtansine (Roche Products Pty Limited)
Active ingredients
trastuzumab emtansine
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Trastuzumab emtansine, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease after pre-operative systemic treatment that included HER2-targeted therapy.